Enhanced Drug Delivery System Using Mesenchymal Stem Cells and Membrane-Coated Nanoparticles

Area of Science:

• Biomedical Engineering
• Cell Therapy
• Nanotechnology

Background:

• Mesenchymal stem cells (MSCs) are emerging as a viable platform for drug delivery systems (DDS).
• MSC-based DDS (MSC-DDS) show potential in treating various diseases, but face challenges due to intrinsic limitations and lack of standardized assessment methods for safety, efficacy, and biodistribution.

Purpose of the Study:

• To assess the current status of MSC-based cell therapy, focusing on biodistribution and systemic safety.
• To explore underlying mechanisms of MSCs concerning tumor initiation and propagation risks.
• To review methods for MSC biodistribution, pharmacokinetics, and pharmacodynamics, and highlight technologies to enhance MSC-DDS.

Main Methods:

• Exploration of MSC biodistribution methods, pharmacokinetics, and pharmacodynamics.
• Review of enhancing technologies: nanotechnology, genome engineering, and biomimetic technology.
• Application of statistical analyses including ANOVA, Kaplan Meier, and log-rank tests.
• Development of a shared DDS medication distribution network using enhanced particle swarm optimization (E-PSO).

Main Results:

• Highlighted the potential of MSCs in gene and drug delivery, including membrane-coated MSC nanoparticles.
• Identified challenges in clinical translation due to the lack of standardized safety and efficacy assessment methodologies.
• Demonstrated the utility of E-PSO for optimizing drug distribution networks in DDS.

Conclusions:

• MSC-based drug delivery systems offer significant therapeutic potential but require standardized methodologies for clinical advancement.
• Emerging technologies like nanotechnology and genome engineering are crucial for enhancing MSC-DDS effectiveness and safety.
• Further research into MSC mechanisms and optimized delivery strategies is essential to fully realize their clinical applications.